A FOXO4-DRI certificate of analysis should name a method for every number it reports: mass spectrometry for identity, RP-HPLC area percent for purity, and a separate assay for net peptide content. Mass spectrometry cannot confirm D-amino acid configuration, so the retro-inverso claim usually rests on synthesis records rather than measurement.
- A certificate of analysis describes one lot on one date and does not by itself prove the vial you received came from that lot.
- Mass spectrometry cannot distinguish D from L amino acids, so a standard identity block does not verify the retro-inverso design of FOXO4-DRI.
- RP-HPLC area percent at 214 nm is a relative measure that excludes anything not absorbing at that wavelength or not eluting within the run.
- Net peptide content, not gross fill weight, governs concentration arithmetic; trifluoroacetate counterions on basic residues can account for a fifth of the powder.
- FOXO4-DRI has no compendial monograph and no marketing authorisation, so every acceptance criterion on its certificate was chosen by the supplier.
What the document is, and what it is not
A certificate of analysis is a statement about one lot of material, produced by whoever ran the tests, on the date those tests were run. It is not a specification, not a warranty, and not evidence that the vial in your hand was filled from the lot described. Those are three separate propositions and sellers routinely blur them into one PDF.
Two different documents circulate under the same name. A certificate of conformance asserts that a lot met a specification and carries no measured values. A certificate of analysis reports results against acceptance criteria, with numbers attached to methods. If the file you were sent has no numbers on it, it is the first kind, whatever the header says, and the correct response is to ask for the second.
For FOXO4-DRI the identity section deserves more scrutiny than it would for an ordinary synthetic peptide, for reasons set out below. Read the header block first anyway, because that is where most defective documents fail before anyone gets to the chemistry.
Header fields and the lot chain
The administrative half of a COA is unglamorous and it is where fabrication shows up soonest. Every field below should be present, legible, and internally consistent with the others.
| Field | What it should say | Failure mode |
|---|---|---|
| Product name and sequence | Compound name plus the one-letter or three-letter sequence, with the stereochemistry stated | Name only, no sequence, so nothing can be checked against the literature |
| Lot or batch number | A manufacturer-assigned identifier that also appears on the vial label | Lot number that is simply the order date, or a blank field filled in by hand |
| Quantity | Gross fill weight, ideally alongside net peptide content | Gross weight presented as though it were peptide mass |
| Appearance | White to off-white lyophilized powder or cake | Omitted, which removes the only check you can perform on receipt |
| Date of manufacture | Synthesis or fill date | Missing, or later than the test date |
| Date of analysis | When the reported tests were actually run | Conflated with the issue date of the PDF |
| Retest or re-evaluation date | Only where stability data exist for that container and condition | A confident expiry with no study behind it |
| Storage condition | The condition the results are held to describe | Generic boilerplate copied across every product |
| Issuing entity and analyst | Laboratory name, report number, signature or initials | Unsigned, unnumbered, no way to trace the record back |
The lot chain matters more than any single field. Vial label, COA, packing list and invoice should all carry the same lot identifier. If the vial is unlabelled or labelled only with the compound name, the certificate describes material you cannot connect to what you received, and no amount of good chemistry on the document repairs that.
Identity: what mass spectrometry proves, and where it stops
FOXO4-DRI as published is a D-retro-inverso construct. The parent sequence is reversed end to end and rebuilt from D-amino acids, and it is joined to a cell-penetrating import segment. The design intent is that side-chain topology approximates the parent L-peptide while the backbone presents nothing a mammalian protease recognises. Baar and colleagues described the peptide and its interference with the FOXO4 to p53 interaction in Cell in 2017, and that paper is the reference point for any sequence a supplier prints.
Now the problem with the identity block. Mass spectrometry measures mass. An all-D peptide and its all-L enantiomer have identical elemental composition and identical mass to every decimal place any instrument reports. The retro-inverso construct and a plain reversed L-sequence are equally indistinguishable. So is a scrambled sequence of the same residue composition, unless fragmentation data are included. A typical identity block gives one calculated mass, one observed mass and a tolerance of a fraction of a Dalton. It confirms formula. It says nothing about stereochemistry, which is the entire premise of this molecule.
So ask what the report actually contains:
- Whether the calculated mass is average or monoisotopic. Near 5 kDa the two differ by a couple of Daltons, and a report that does not say which is being quoted has left the tolerance meaningless.
- Ionisation mode, and whether the raw charge envelope or only a deconvoluted number is available.
- Any sequence-level evidence at all: MS/MS fragmentation, or Edman degradation. Note that standard PTH-amino acid chromatography runs on achiral columns, so Edman gives order without giving configuration.
- Whether chirality was tested. On research-peptide certificates the answer is almost always no.
Configuration is verifiable, just not by the methods vendors pay for. Total acid hydrolysis followed by derivatisation with Marfey's reagent and RP-HPLC separates D from L amino acids; chiral GC-MS of volatile derivatives does the same job. Circular dichroism is the cheap orthogonal check on bulk material, since an all-D peptide gives a spectrum that is the mirror image of its all-L counterpart. None of these appear on the certificates in general circulation, which means the D-configuration claim rests on the synthesis record and the building blocks purchased. If that claim carries weight in your experiment, budget for the chiral assay and treat the COA as silent on the point.
Purity by RP-HPLC: read the method, not the number
Purity on a peptide COA almost always means area percent by reversed-phase HPLC: the main peak's integrated area divided by the total integrated area of everything the detector saw. That is a relative measure. It does not report how much peptide is in the vial, and it cannot see anything that fails to absorb at the detection wavelength or fails to elute within the run.
| Method field | Typical entry | Effect on the result |
|---|---|---|
| Column chemistry and dimensions | C18, 4.6 × 250 mm, 5 µm | Sets the resolving power; short columns merge close-eluting deletion sequences into the main peak |
| Mobile phase | Water and acetonitrile, 0.1% TFA | Ion pairing controls peak shape for a basic, arginine-rich peptide |
| Gradient span and run time | Stated percentages over stated minutes | Truncated runs leave hydrophobic impurities on the column, uncounted |
| Detection wavelength | 214 nm | Reads the amide backbone, so it does not depend on aromatic residue content the way 280 nm does |
| Injection load | Micrograms on column | Overload broadens and fronts the main peak, flattering the area percent |
| System suitability | Tailing factor, plate count, resolution, repeatability | Establishes that the separation was fit to report at all, per USP General Chapter <621> |
| Integration evidence | Chromatogram with axes and labelled peaks | Without the trace, the percentage is an assertion |
A phrase that should stop you is "98% by HPLC-MS". Purity by chromatography and identity by mass spectrometry are two tests with two outputs. Collapsing them into one line usually means someone was writing a template rather than reading an instrument. Similarly, 99.9% on a synthetic peptide of this length is not a number to be pleased about; solid-phase synthesis of a long, arginine-rich sequence carries deletion and truncation products at low percentages, and a certificate claiming they are absent is claiming something unusual without showing the trace that would support it.
Net peptide content: the number that changes your arithmetic
Gross fill weight is powder. Powder is peptide plus counterions plus residual water plus whatever salt survived the final step. Peptides purified by preparative HPLC in trifluoroacetic acid come off as TFA salts, and each basic residue can carry a counterion. FOXO4-DRI includes an arginine-rich import segment, so the counterion load sits at the heavy end of the usual range. Net peptide content for material like this commonly lands somewhere between 70% and 85%, and it is measured by amino acid analysis, elemental nitrogen determination, or quantitative NMR against a certified internal standard.
Where the certificate omits net peptide content, the mass of actual peptide in the vial is unknown to within roughly a quarter. Here is what that does to a solution record. Take a vial filled at 5 mg gross with a measured net peptide content of 78%, brought into 2 mL of diluent:
5 mg × 0.78 = 3.9 mg peptide
3.9 mg ÷ 2 mL = 1.95 mg/mL
The assumption that gross weight is peptide weight would have written 2.5 mg/mL into the notebook. That is a 22% overstatement carried silently into every subsequent calculation, and it is invisible in the data. The vial concentration calculator works on whatever mass you enter, so enter the corrected figure rather than the label figure. The same correction belongs in any price comparison; the cost per mg tool gives a different ranking when one supplier quotes peptide content and another quotes powder.
Ash content, residual solvent by GC headspace, and water by Karl Fischer titration are the adjacent tests. Few research-peptide certificates carry them. Their absence is normal rather than damning, but it does mean the mass balance on the vial is unclosed.
Verifying at the laboratory rather than with the seller
A PDF supplied by the party selling the material is a claim by that party, including the parts of it attributed to someone else. Verification means going to the entity whose name is on the report. The sequence is short and most of it can be done in a morning.
- Take the issuing laboratory's name from the certificate. Find its contact details independently, through a company register or a professional directory, not from the footer of the PDF or a link on the vendor's site.
- Quote the report number and the lot number and ask two questions: does this report exist, and to whom was it issued. Some contract labs will confirm both; some will only confirm to the client of record, which is itself informative.
- Request the underlying data. A full chromatogram with axes, retention times and the injection timestamp, and the raw or deconvoluted mass spectrum. A cropped screenshot pasted into a template is not data.
- Compare the method text against the trace. Run time, wavelength, gradient and retention times should agree with what the header claims. Fabricated documents fail here constantly because the text is edited and the image is not.
- Compare chromatograms across two lots you have been sent. Identical baseline noise between supposedly separate injections means one trace was reused.
- Ask whether a retain sample is held and whether the lab will re-run on request. Independent laboratories generally will, at a price that is usually a small fraction of the material cost.
If the issuing entity turns out to be the vendor's own quality function, the document is an internal record. That is not worthless. In-house QC on a real instrument, with real system suitability, is better than nothing and better than most. It is simply not third-party, and it should be described that way in your own procurement file. Our quality standard page sets out which tests we commission externally and which we run internally, for the same reason.
Red flags
| What you see | What it usually means |
|---|---|
| Purity given without a method or a wavelength | The number was typed, not measured |
| Test date earlier than manufacture date | Template reuse; the dates were never reconciled |
| No net peptide content anywhere on the page | The vial mass is unresolved to within roughly a quarter |
| "Pharmaceutical grade" on a research chemical | A marketing phrase with no regulatory definition attached |
| Sequence printed does not match the published construct | Different material, transcription error, or neither party checked |
| Mass reported without stating average or monoisotopic | Whoever wrote the report was not reading the instrument output |
| PDF document properties naming another compound | One template, many products, edited by hand |
| No analyst name, signature or report number | Nothing to verify against at the laboratory |
None of these prove the material is wrong. They tell you the document cannot be relied on to say the material is right, which for a compound whose defining feature is invisible to routine analysis is close to the same thing in practice. Storage and diluent records sit alongside the certificate in the same file; the diluent guide covers what belongs in that part of the record.
Regulatory position
FOXO4-DRI holds no marketing authorisation in the United States, the European Union or any other major jurisdiction. There is no FDA-approved product containing it. The published record is preclinical, centred on cell culture and mouse work reported by Baar and colleagues in 2017 and subsequent laboratory studies.
There is also no United States Pharmacopeia monograph for this peptide. That absence has a direct consequence for certificate reading: no compendial identity test, purity limit or impurity threshold exists to compare against. Every acceptance criterion on a FOXO4-DRI certificate was chosen by the supplier. ICH Q6A describes what a specification is supposed to look like, and it is a reasonable yardstick, but nobody is obliged to meet it here.
Status verified 26 August 2026.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
Common questions
Does a mass spectrum confirm that the material is the D-retro-inverso form?
What purity figure is realistic for a peptide of this length?
Why does net peptide content matter if the purity is already 98%?
How do I check a certificate with the issuing laboratory?
Is an in-house certificate from the supplier worth anything?
Is there a USP monograph or official specification for FOXO4-DRI?
Sources
- Baar et al., Cell, 2017. Reports the design and preclinical characterisation of the FOXO4-DRI peptide, including its D-retro-inverso construction and its interference with the FOXO4 to p53 interaction; the reference point for any sequence printed on a certificate.
- USP General Chapter <621> Chromatography. Defines system suitability parameters such as resolution, tailing factor, plate count and repeatability; supports the position that an area percent purity figure is only interpretable alongside the method and suitability data.
- ICH Q6A, Specifications for New Drug Substances and New Drug Products. Establishes the principle that a specification pairs each test with an analytical procedure and a numeric acceptance criterion; used here as the yardstick a research-grade certificate is measured against.
- Peer-reviewed methodology on Marfey's reagent (1-fluoro-2,4-dinitrophenyl-5-L-alanine amide) derivatisation. Established chromatographic approach for determining amino acid configuration after total hydrolysis; supports the claim that D versus L assignment requires a chiral method rather than mass spectrometry.